PD-1 and PD-L1 expression in rare lung tumors.

IF 2.3 4区 医学 Q3 ONCOLOGY
Pathology & Oncology Research Pub Date : 2023-05-18 eCollection Date: 2023-01-01 DOI:10.3389/pore.2023.1611164
Marton Gyulai, Zsolt Megyesfalvi, Lilla Reiniger, Tunde Harko, Bence Ferencz, Luca Karsko, Laszlo Agocs, Janos Fillinger, Balazs Dome, Zoltan Szallasi, Judit Moldvay
{"title":"PD-1 and PD-L1 expression in rare lung tumors.","authors":"Marton Gyulai, Zsolt Megyesfalvi, Lilla Reiniger, Tunde Harko, Bence Ferencz, Luca Karsko, Laszlo Agocs, Janos Fillinger, Balazs Dome, Zoltan Szallasi, Judit Moldvay","doi":"10.3389/pore.2023.1611164","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Our knowledge is still limited about the characteristics and treatment of rare lung tumors. The aim of our study was to determine programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) expression in rare pulmonary tumors to assess the potential role of immunotherapy. <b>Methods:</b> 66 pathologically confirmed rare lung tumors including 26 mucoepidermoid carcinomas (MECs), 27 adenoid cystic carcinomas (ACCs), and 13 tracheobronchial papillomas (TBPs) were collected retrospectively. Immunohistochemical (IHC) staining was performed on formalin fixed paraffin embedded (FFPE) tumor tissues, and PD-L1 expression on tumor cells (TCs) and immune cells (ICs), and PD-1 expression on ICs were determined. The cut off value for positive immunostaining was set at 1% for all markers. <b>Results:</b> PD-L1 expression on TCs was observed in two cases of MEC (7.7%), one case of ACC (3.7%), and was absent in TBP samples. PD-L1 expression on ICs could be demonstrated in nine cases of MEC (34.6%), four cases of ACC (14.8%), and was absent in TBPs. All PD-L1 TC positive tumors were also PD-L1 IC positive. Higher expression level than 5% of PD-L1 TC and/or IC was observed only in one ACC and in two MEC patients. Among them, strong PD-L1 immunopositivity of >50% on TCs and of >10% on ICs could be demonstrated in one MEC sample. PD-L1 expression of ≥1% on ICs was significantly more common in MEC, than in TBP (<i>p</i> < 0.001). In MEC ≥1% PD-L1 TC or IC expressions were significantly more common in patients aged 55 or older, than in younger patients (<i>p</i> = 0.046, and <i>p</i> = 0.01, respectively). PD-1 expression on ICs was found in five cases of MEC (19.2%), four cases of ACC (14.8%), and in two cases of TBP (15.4%). Only one MEC case showed a higher than 5% expression level of PD-1 on ICs. <b>Conclusion:</b> This retrospective study comprehensively demonstrated the rare expression of PD-L1 and PD-1 in pulmonary MEC, ACC, and TBP. However, we found very strong PD-L1 immunopositivity on both TCs and ICs in one MEC sample, which warrants further investigations in a larger cohort.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232779/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2023.1611164","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Our knowledge is still limited about the characteristics and treatment of rare lung tumors. The aim of our study was to determine programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) expression in rare pulmonary tumors to assess the potential role of immunotherapy. Methods: 66 pathologically confirmed rare lung tumors including 26 mucoepidermoid carcinomas (MECs), 27 adenoid cystic carcinomas (ACCs), and 13 tracheobronchial papillomas (TBPs) were collected retrospectively. Immunohistochemical (IHC) staining was performed on formalin fixed paraffin embedded (FFPE) tumor tissues, and PD-L1 expression on tumor cells (TCs) and immune cells (ICs), and PD-1 expression on ICs were determined. The cut off value for positive immunostaining was set at 1% for all markers. Results: PD-L1 expression on TCs was observed in two cases of MEC (7.7%), one case of ACC (3.7%), and was absent in TBP samples. PD-L1 expression on ICs could be demonstrated in nine cases of MEC (34.6%), four cases of ACC (14.8%), and was absent in TBPs. All PD-L1 TC positive tumors were also PD-L1 IC positive. Higher expression level than 5% of PD-L1 TC and/or IC was observed only in one ACC and in two MEC patients. Among them, strong PD-L1 immunopositivity of >50% on TCs and of >10% on ICs could be demonstrated in one MEC sample. PD-L1 expression of ≥1% on ICs was significantly more common in MEC, than in TBP (p < 0.001). In MEC ≥1% PD-L1 TC or IC expressions were significantly more common in patients aged 55 or older, than in younger patients (p = 0.046, and p = 0.01, respectively). PD-1 expression on ICs was found in five cases of MEC (19.2%), four cases of ACC (14.8%), and in two cases of TBP (15.4%). Only one MEC case showed a higher than 5% expression level of PD-1 on ICs. Conclusion: This retrospective study comprehensively demonstrated the rare expression of PD-L1 and PD-1 in pulmonary MEC, ACC, and TBP. However, we found very strong PD-L1 immunopositivity on both TCs and ICs in one MEC sample, which warrants further investigations in a larger cohort.

罕见肺部肿瘤中 PD-1 和 PD-L1 的表达。
背景:我们对罕见肺肿瘤的特征和治疗方法的了解仍然有限。我们的研究旨在确定罕见肺肿瘤中程序性细胞死亡配体-1(PD-L1)和程序性细胞死亡-1(PD-1)的表达,以评估免疫疗法的潜在作用。方法:回顾性收集了66例经病理证实的罕见肺肿瘤,包括26例粘液表皮样癌(MEC)、27例腺样囊性癌(ACC)和13例气管支气管乳头状瘤(TBPs)。对福尔马林固定石蜡包埋(FFPE)的肿瘤组织进行免疫组化(IHC)染色,测定肿瘤细胞(TC)和免疫细胞(IC)的 PD-L1 表达以及 IC 的 PD-1 表达。所有标记物免疫染色阳性的临界值均设定为1%。结果在两例 MEC(7.7%)和一例 ACC(3.7%)中观察到 TC 上有 PD-L1 表达,而在 TBP 样本中则没有。9例MEC(34.6%)、4例ACC(14.8%)和TBP样本中均未发现PD-L1在IC上表达。所有 PD-L1 TC 阳性的肿瘤同时也是 PD-L1 IC 阳性。只有一名 ACC 和两名 MEC 患者的 PD-L1 TC 和/或 IC 表达水平高于 5%。其中,在一个 MEC 样本中,TC 上的 PD-L1 免疫阳性率大于 50%,IC 上的 PD-L1 免疫阳性率大于 10%。集成电路上 PD-L1 表达≥1%的情况在 MEC 中明显多于 TBP(p < 0.001)。在 MEC 中,PD-L1 TC 或 IC 表达≥1% 的 55 岁或以上患者明显多于年轻患者(分别为 p = 0.046 和 p = 0.01)。有 5 例 MEC(19.2%)、4 例 ACC(14.8%)和 2 例 TBP(15.4%)患者的 IC 上发现有 PD-1 表达。只有一个 MEC 病例的 IC 上 PD-1 表达水平高于 5%。结论这项回顾性研究全面证实了 PD-L1 和 PD-1 在肺 MEC、ACC 和 TBP 中的罕见表达。然而,我们发现在一个 MEC 样本中,TC 和 IC 上的 PD-L1 免疫阳性率都很高,这就需要在更大的队列中进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
134
审稿时长
4-8 weeks
期刊介绍: Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信